Convergence Investment Partners, LLC Supernus Pharmaceuticals, Inc. Transaction History

Convergence Investment Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $859,337 - $1.14 Million	-20,125 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$44.1 - $59.85 $810,734 - $1.1 Million	-18,384 Reduced 47.74%	20,125 $1.2 Million
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $402,557 - $508,208	-10,836 Reduced 21.96%	38,509 $1.76 Million
Q4 2017 Jan 16, 2018	BUY	$36.4 - $42.6 $86,814 - $101,601	2,385 Added 5.08%	49,345 $1.97 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $1.73 Million - $2.33 Million	46,960	46,960 $1.88 Million

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Convergence Investment Partners, LLC with notifications on news.